Bavo Heeman
Radboud University Nijmegen Medical Centre
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Bavo Heeman.
Journal of Cell Science | 2011
Bavo Heeman; Chris Van den Haute; Sarah-Ann Aelvoet; Federica Valsecchi; Richard J. Rodenburg; Veerle Reumers; Zeger Debyser; Geert Callewaert; Werner J.H. Koopman; Peter H. G. M. Willems; Veerle Baekelandt
Loss-of-function mutations in the gene encoding the mitochondrial PTEN-induced putative kinase 1 (PINK1) are a major cause of early-onset familial Parkinsons disease (PD). Recent studies have highlighted an important function for PINK1 in clearing depolarized mitochondria by mitophagy. However, the role of PINK1 in mitochondrial and cellular functioning in physiological conditions is still incompletely understood. Here, we investigate mitochondrial and cellular calcium (Ca2+) homeostasis in PINK1-knockdown and PINK1-knockout mouse cells, both in basal metabolic conditions and after physiological stimulation, using unbiased automated live single-cell imaging in combination with organelle-specific fluorescent probes. Our data reveal that depletion of PINK1 induces moderate fragmentation of the mitochondrial network, mitochondrial membrane depolarization and increased production of reactive oxygen species. This results in reduced uptake of Ca2+ by mitochondria after physiological stimulation. As a consequence, cells with knockdown or knockout of PINK1 display impaired mitochondrial ATP synthesis, which is exacerbated under conditions of increased ATP demand, thereby affecting cytosolic Ca2+ extrusion. The impairment in energy maintenance was confirmed in the brain of PINK1-knockout mice by in vivo bioluminescence imaging. Our findings demonstrate a key role for PINK1 in the regulation of mitochondrial homeostasis and energy metabolism under physiological conditions.
Gene Therapy | 2011
A. Van der Perren; Jaan Toelen; Marianne Carlon; C Van den Haute; Frea Coun; Bavo Heeman; Veerle Reumers; Luk H. Vandenberghe; James M. Wilson; Zeger Debyser; Veerle Baekelandt
Dysfunction of the nigrostriatal system is the major cause of Parkinsons disease (PD). This brain region is therefore an important target for gene delivery aiming at disease modeling and gene therapy. Recombinant adeno-associated viral (rAAV) vectors have been developed as efficient vehicles for gene transfer into the central nervous system. Recently, several serotypes have been described, with varying tropism for brain transduction. In light of the further development of a viral vector-mediated rat model for PD, we performed a comprehensive comparison of the transduction and tropism for dopaminergic neurons (DNs) in the adult Wistar rat substantia nigra (SN) of seven rAAV vector serotypes (rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9). All vectors were normalized by titer and volume, and stereotactically injected into the SN. Gene expression was assessed non-invasively and quantitatively in vivo by bioluminescence imaging at 2 and 5 weeks after injection, and was found to be stable over time. Immunohistochemistry at 6 weeks following injection revealed the most widespread enhanced green fluorescence protein expression and the highest number of positive nigral cells using rAAV 2/7, 2/9 and 2/1. The area transduced by rAAV 2/8 was smaller, but nevertheless almost equal numbers of nigral cells were targeted. Detailed confocal analysis revealed that serotype 2/7, 2/9, 2/1 and 2/8 transduced at least 70% of the DNs. In conclusion, these results show that various rAAV serotypes efficiently transduce nigral DNs, but significant differences in transgene expression pattern and level were observed.
Biochimica et Biophysica Acta | 2012
Federica Valsecchi; Claire Monge; Marleen Forkink; Ad J.C. de Groof; Giovanni Benard; Rodrigue Rossignol; Herman G. Swarts; Sjenet E. van Emst-de Vries; Richard J. Rodenburg; Maria Antonietta Calvaruso; Leo Nijtmans; Bavo Heeman; Peggy Roestenberg; Bé Wieringa; Jan A.M. Smeitink; Werner J.H. Koopman; Peter H.G.M. Willems
Human mitochondrial complex I (CI) deficiency is associated with progressive neurological disorders. To better understand the CI pathomechanism, we here studied how deletion of the CI gene NDUFS4 affects cell metabolism. To this end we compared immortalized mouse embryonic fibroblasts (MEFs) derived from wildtype (wt) and whole-body NDUFS4 knockout (KO) mice. Mitochondria from KO cells lacked the NDUFS4 protein and mitoplasts displayed virtually no CI activity, moderately reduced CII, CIII and CIV activities and normal citrate synthase and CV (F(o)F(1)-ATPase) activity. Native electrophoresis of KO cell mitochondrial fractions revealed two distinct CI subcomplexes of ~830kDa (enzymatically inactive) and ~200kDa (active). The level of fully-assembled CII-CV was not affected by NDUFS4 gene deletion. KO cells exhibited a moderately reduced maximal and routine O(2) consumption, which was fully inhibited by acute application of the CI inhibitor rotenone. The aberrant CI assembly and reduced O(2) consumption in KO cells were fully normalized by NDUFS4 gene complementation. Cellular [NAD(+)]/[NADH] ratio, lactate production and mitochondrial tetramethyl rhodamine methyl ester (TMRM) accumulation were slightly increased in KO cells. In contrast, NDUFS4 gene deletion did not detectably alter [NADP(+)]/[NADPH] ratio, cellular glucose consumption, the protein levels of hexokinases (I and II) and phosphorylated pyruvate dehydrogenase (P-PDH), total cellular adenosine triphosphate (ATP) level, free cytosolic [ATP], cell growth rate, and reactive oxygen species (ROS) levels. We conclude that the NDUFS4 subunit is of key importance in CI stabilization and that, due to the metabolic properties of the immortalized MEFs, NDUFS4 gene deletion has only modest effects at the live cell level. This article is part of a special issue entitled: 17th European Bioenergetics Conference (EBEC 2012).
Journal of Parkinson's disease | 2011
Anne-Sophie Van Rompuy; Bavo Heeman; Chris Van den Haute; Veerle Baekelandt
Parkinsons disease is a common neurodegenerative disorder whose aetiology is not yet fully understood. In the past ten years, the discovery of genes linked to hereditary forms of the disease has impelled the development of animal models. These should lead to the identification of novel pathways that provide insight into the functionality of the proteins involved and the pathogenesis of the sporadic forms of the disease. In particular, loss-of-function mutations in the parkin and PINK1 (phosphatase and tensin homolog (PTEN)-induced kinase 1) genes account for most of the cases of familial autosomal recessive parkinsonism. Both parkin and PINK1 knockout rodent models are now available, which display an overall mild phenotype consisting of a mitochondrial dysfunction together with changes in dopamine metabolism and oxidative stress. However, up till now these models fail to reproduce the main hallmarks of Parkinsons disease: the dopaminergic cell loss in the substantia nigra and the presence of cytoplasmic inclusions, named Lewy bodies, in the remaining dopaminergic neurons. We here review the most important knockout and knockdown rodent models generated so far for these two recessive Parkinsons disease-causing genes. We critically feature their main characteristics and their impact on the research field, and propose some future directions for the study and modelling of the loss of function of parkin and PINK1 in rodents.
Archive | 2013
Bavo Heeman; Mustafa Varçin; Sophie Sarre; Rudi D'Hooge; Veerle Baekelandt; Chris Van den Haute
Archive | 2011
Mustafa Varçin; Birgit Mertens; Bavo Heeman; Chris Van den Haute; Veerle Baekelandt; Yvette Michotte; Sophie Sarre
Archive | 2011
Bavo Heeman; Chris Van Den Haute; Sarah-Ann Aelvoet; Veerle Reumers; Rik Gijsbers; Werner J.H. Koopman; Peter H.G.M. Willems; Zeger Debyser; Veerle Baekelandt
Archive | 2010
Mustafa Varçin; Brigitte Mertens; Bavo Heeman; Chris Van den Haute; Veerle Baekelandt; Yvette Michotte; Sophie Sarre
Archive | 2010
Chris Van den Haute; Bavo Heeman; Sarah-Ann Aelvoet; Werner J.H. Koopman; Peter H. G. M. Willems; Zeger Debyser; Veerle Baekelandt
Movement Disorders | 2010
Bavo Heeman; Chris Van den Haute; Sarah-Ann Aelvoet; Federica Valsecchi; Richard J. Rodenburg; Zeger Debyser; W H Koopman; Phgm Willems; Veerle Baekelandt